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Abstract  
 
Objective:  To investigate the association between current CD4+ T-cell count and CD4/CD8+ 
ratio with severity of frailty among people aging with HIV.  
Methods: Cross-sectional observational study analysing data from all study visits in the 
ongoing prospective Modena HIV Metabolic Clinic Cohort between 2006 and 2015. Frailty 
severity was assessed using a frailty index (FI). We visualized the relationships between 
frailty index score and current CD4 cell count and CD4/CD8 ratio on two different curves 
adjusted for age, sex, and duration of HIV infection. 
Results:  
Frailty index scores exhibited an inverse relationship with current CD4 count, up to 900 
cells/µL. The CD4/CD8 ratio was inversely correlated with frailty index both below and 
above the cut-off of 900 CD4 cells/µL. 
Conclusions:  
Frailty in PLWH is inversely associated with both immune-activation, depicted by CD4/CD8 
ratio and immune-deficit depicted by CD4 count. The first association shows a linear shape 
while the second shows a hook-shape with a turning point at 900 cells. Above this cut off 
level CD4 do not represent a significant risk factor for frailty. 
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Introduction 
Aging is associated with an increased risk of several adverse health outcomes, including 
illnesses, disabilities and death. The aging process has great inter-variability, and those at 
increased risk of adverse outcomes are said to be frail [1,2]. This is also true within groups 
of people suffering from the same disease, including people living with HIV (PLWH) [3-5].   
 
With the aging of PLWH, we urgently need to better understand how the progression of 
frailty might be prevented or delayed among this group. Current CD4+ T-cell count is the 
modifiable covariate most often associated with frailty [3-10]. This relationship has proven 
tricky to understand, as several recent reports identified no association between CD4 cell 
count and severity of frailty, especially among study participants with higher current CD4 
cell counts [11-14].  
 
This inconsistency may reflect the fact that immune status and aging contribute to frailty in 
complex ways [15,16]. CD4 cell depletion is associated with a shortened life expectancy, in 
part due to an increased risk for inflammatory, age-related chronic conditions, including 
heart disease and cancers [17-19]. Conversely, higher CD4 counts are associated with longer 
life expectancy and appear to be protective against these diseases [20,21]. This can 
paradoxically confer risk of other age-related conditions, given that people with higher CD4 
counts generally live longer and the strongest risk factor for frailty and for many chronic 
inflammatory diseases is aging itself [22]. 
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Based on this understanding, our group previously proposed a theoretical U-shaped 
association between current CD4 count and frailty severity among PLWH [23].  
Greater severity of frailty may be associated with lower CD4 counts among some patients, 
while also being associated with higher CD4 counts among patients who survive to older 
ages and accumulate traditional risk factors for age-related diseases and frailty, 
independently of effective antiretroviral therapy [24].  
 
Further complicating this relationship, immune depletion and chronic immune activation 
each appear to contribute to risk for inflammatory, age-related diseases among PLWH [25]. 
Both chronic HIV infection and aging lead to T cell activation and progressive accumulation 
of terminally differentiated T cells (e.g. CD8+ effector cells), a reduction in naïve T cells, a 
lower CD4/CD8 ratio, and increased levels of multiple inflammatory markers [26]. This leads 
to a state of immune senescence characterized by low-level chronic inflammation and an 
impaired ability to mount adequate immune response to challenges [27]. CD4/CD8 ratio is a 
surrogate marker of immune senescence [28], and is inversely correlated with the risk for 
inflammatory and/or age-related disease [7,29-32]. 
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In this study, our primary objective was to assess if a large cohort of people aging with HIV 
demonstrates this U-shaped relationship between current CD4 count and severity of frailty 
on both down-sloping and up-sloping portions of the U-curve.  
 
Our secondary objective was to assess the relationship between frailty severity and current 
CD4/CD8 ratio. We hypothesized that CD4/CD8 ratio would be inversely associated with 
frailty in both portions. 
 
Methods 
Data were collected from participants attending the ongoing prospective Modena HIV 
Metabolic Clinic (MHMC) Cohort Study [33,34], undergoing effective antiretroviral (ART) 
treatment (viral load <40 copies/ml), with available frailty and viro-immunological 
assessments, having accessed the clinic from January 2006 to December 2015.  
Exclusion criteria were detectable viral load, both at baseline and in any subsequent visits, 
i.e. patients were censored if they were found with detectable viral load.  
This outpatient clinic is a multidisciplinary tertiary care centre for the management of non-
infectious comorbidities in HIV infected patients followed both at the Modena HIV Metabolic 
Clinic and from HIV care centres throughout Italy. 
The association between frailty index and CD4 and CD8 cell count was assessed at each study 
visit, so that individuals could contribute more than once. 
Frailty severity was assessed using a 37-item frailty index, as previously described [3].  
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A frailty index calculates the proportion of age-related health deficits that a person has 
accumulated out of a selection of at least 30 health variables, 37 in our setting. Health 
variables used to calculate frailty index are shown in S1 Table. Any health variable (e.g. signs 
and symptoms of disease, laboratory measures, and self-reported data) can be included as 
an item in a frailty index as long as the variables describe potential age-related health 
problems, and as a group include multiple physiological systems [35]. The frailty index 
approach is among the most common methods of measuring frailty [36]. Frailty was defined 
as FI value above a cut off of 0.31 as it was representative of the median of the individuals in 
the cohort and similar to previous published studies by our cohort. 
 
For the purpose of description, we also depict the proportion of patients with Physical frailty 
Phenotype (PFP) in a subset of patients in which this data was available using Fried criteria 
[37]. The FPP is based on a pre-defined set of five criteria exploring the presence/absence of 
signs or symptoms (involuntary weight loss, exhaustion, slow gait speed, poor handgrip 
strength, and sedentary behaviour).  
  
Current CD4 count was measured as a continuous variable: for descriptive purpose, we 
reported CD4 count with actual values, while it was rescaled to 100 cell/µL when included 
as a covariate in linear regression model. Other covariates were age and duration of HIV 
infection (measured continuously) and sex.  
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We used Generalized Estimating Equations (GEE) to assess relationships between frailty 
index score and current CD4 count, adjusting for age, sex and duration of HIV infection, and 
visualized this relationship using Lowess curves. In this model, each observation was 
computed as a single measurement, with no adjustment to weight multiple observation for 
each patient. Based on the shape of the resulting curve, we identified the strength of 
relationships between CD4 count and frailty in both down-sloping and up-sloping portions 
of the curve. Statistical significance was set at p ≤ 0.05. Data were analyzed using STATA 
Software package, Intercooled version 13.1 for Mac (Stata Corp ltd, Collage Station, TX, USA).  
 
The Research Ethics Board of the University of Modena and Reggio Emilia provided approval 
for the Modena HIV Metabolic Clinic Cohort Study. All study participants provided written 
consent. 
 
Results 
We included 2,915 participants, accounting for 10,686 total observations with median 
number of 4 observations per patient (IQR 2-7, range: 1-16). The observation follow-up 
period was 4.2 years (IQR 2.1-6.1). In this time frame 36 patients died: 11 of cancer, 4 of CVD, 
5 of liver failure, 1 1 in a motor vehicle collision, 15 of unknown causes. 
The mean age of the cohort at last observation was 48 ± 8.2, and 68% were men.  
Table 1 summarizes demographic and clinical characteristics of the study population at 
baseline: median current CD4 count was 567 (418–747), current CD4/CD8=0.71 (IQR 0.48- 
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1.00, data available in 2030 observations, and median duration of HIV infection was 19 (IQR 
13-24) years.  
At last visit median CD4 was 639 (IQR 466-835) and Cd4/CD8 was 0.80 (IQR 0.56-1.10; data 
available in 2,494 observations).  
At baseline, median frailty index score was 0.31 (IQR 0.24–0.39), PFP was available in 482 
patients. As classified by the frailty phenotype categories, 3.1% (15) of participants were 
considered to be frail, 51.9% (250) were pre-frail, and 45.0% (217) of participants were 
robust. 
Using a Lowess smoothing curve, frailty index exhibited a hook-shaped relationship with 
current CD4 count (Fig 1). S1 Fig restricts this association at first (panel A) and last (panel 
B) observation per patient. 
After visualization of the Lowess curves, we generated different models with different cut-
offs of CD4 cell count near to the turning point of the curve. We identified a threshold of 900 
CD4 cell/µL as the best turning point of ß coefficients for CD4 (Fig 1). 517 participants had 
current CD4 counts above 900 cells/µL at last visit. 
Frailty index (per 0.01 increase) and CD4 count had an inverse relationship below 900 
cells/µL (a total of 9048 observations were analysed, ß = -0.45, -0.58 to -0.32, p<0.001, per 
100 cells/µL) and a borderline relationship above 900 cells/µL (1638 observations, ß = 0.23, 
0.0002 to 0.46, p=0.049, per 100 cell/µL) after adjustment for age, sex, and duration of HIV 
infection.  
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In a subset of 2756 participants accounting for a total of 8975 observations, we evaluated 
the association between frailty and the CD4/CD8 ratio below and above the level of 900 CD4 
cells/µL. Lowess graph was drawn to depict the relationship between frailty index and 
CD4/CD8 ratio (Fig 2).  
This sample was used to build multivariable GEE linear regression to explore the association 
between frailty index score and CD4 <900 cells (Fig 3A) and CD4 >900 cells (Fig 3B) 
respectively, after adjustment for age, sex, and duration of HIV infection. 
 
In the first model (Fig 3A) frailty index score (per 0.01 increase) was inversely related with 
CD4 count (per any 100 cells increase) ß = -0.45 (-0.58; -0.32, p<0.001) and CD4/CD8 ß = -
2.23 (-2.97; -1.48, p<0.001). It was also directly related to age ß = 1.36, male sex ß = 2.27 and 
duration of HIV infection (per 10-year increment) ß = 1.97. 
 
In the second model (Fig 3B) frailty index score was only borderline related with CD4 count 
ß = 0.31 (0.07; 0.056) and inversely related with CD4/CD8 ß = -3.13 (-4.56; -1.71, p<0.001) 
and directly related to age ß = 1.43 (0.53-2.33). 
 
Discussion  
We analysed a large sample of people aging with HIV, with a relatively low prevalence of 
phenotypically frail individuals. 
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We identified a hook-shaped relationship between severity of frailty (assessed by a frailty 
index of 37 health variables that describes potential age-related health problems) and 
current CD4 count.  
In this study, we chose to describe frailty using a validated frailty index which has the 
advantage of being a continuous variable to be plotted with the numerical value of CD4 or 
CD4/CD8. We arbitrary defined frailty using a cut off value above the median in the cohort 
(FI>0.31). This frailty categorisation is not comparable with the physical frailty phenotype 
case definition, nevertheless it can be understood as the pre-frailty status depicted by Fried 
definition and present in 52% of our patients’ cohort. However, we have previously shown 
in a study comparing FI and PFP evaluated in the same population that FI had a stronger 
association with age, nadir CD4 count, comorbidities, falls, and disability, suggesting that this 
tool is more applicable in clinical settings [38]. 
 
An inverse relationship between frailty severity and CD4 count was identified below a cut-
off of 900 cells/µL. We believe that this cut off is clinically significant to be used in PLWH. 
First, this value is universally recognised as acceptable even in HIV negative individuals. 
Second, this value is increasingly reached in more recently HIV-infected individuals who 
promptly start ART [39]. Third, it has been shown that PLWH with CD4 count between 500 
and 750 cells still display increased risk of AIDS compared to PLWH with higher CD4 counts 
[40].  
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The inverse relationship between current CD4 count and frailty severity was not evident 
above 900 cells/µL, and a borderline-significant positive relationship was observed after 
adjustment for covariates. This observation requires more investigation. Our interpretation 
is that CD4 count above 900 cell/µl is not a prognostic marker in aging PLWH and in our 
model the major driver for frailty in this population are rather traditional risk factors as age 
and gender.  
Previously published data on the relationship between the degree of frailty and CD4 count 
have shown varied results. Inverse relationships between current CD4 count and frailty have 
been identified among patients presenting for HIV care [3,6,8,9], people living with HIV in 
the community [10], and HIV-positive cohorts of men who have sex with men [5,24], in 
women [7], and in people who inject drugs [4]. Other recent studies have conversely 
identified no relationship between current CD4 count and frailty. Among studies of HIV 
outpatients [11,13], HIV-positive injection drug users [14], and men who have sex with men 
[12], frail and non-frail participants were similar in terms of age and current CD4 count, but 
differed in sex, comorbid conditions, smoking status, and markers of immune activation and 
inflammation. 
Interestingly a marker of immune activation, namely CD4/CD8 ratio is always associated 
with frailty, regardless current CD4 cell count. 
 
One previously reported study identified an inverse relationship between CD4/CD8 ratio 
and frailty among people with HIV [7]. A second study identified a non-significant trend 
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towards lower CD4/CD8 ratios in people who were identified as frail compared to those who 
were non-frail [6]. 
A desirable intervention to prevent or delay the progression of frailty in HIV patients is early 
initiation of antiretroviral therapy, supporting recovery of the immune system. This strategy, 
already supported by START trial [41] should be confirmed with regards to this outcome. 
 
Our data should be interpreted with caution, given the cross-sectional nature of the study: 
inferences about causality and the independent contributions of immune status and of aging 
to frailty cannot be assessed. More longitudinal research on the relationship between 
immune status and frailty is needed. 
 
In conclusion, our findings of a dynamic relationship between current CD4 count and frailty 
highlight the complexity of the relationship between immune function, aging, and frailty 
among PLWH. We identified a cut-off of 900 cells/µL, below which further depletion of CD4 
cell count is associated with increased frailty. Lower CD4/CD8 ratio, a surrogate marker of 
immune activation, is associated with severity of frailty both below and above this cut-off of 
900 CD4 cells/µL.  
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Supporting information 
 
S1 Table. Frailty index including 37 health variables. 
A frailty index calculates the proportion of age-related health deficits that a person has 
accumulated out of a selection of 37 health variables.  
S1 Fig.  Association between frailty index and current CD4 cell count. 
Frailty index and current CD4 cell count at first (panel A) and last (panel B) observation 
per patient. 
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Table 1. Demographic and clinical characteristics of the study population at baseline. 
 
 Frequency or mean or 
median 
% or SD or IQR 
Median follow-up, years 4.2 years  
 
2.1-6.1 
Women, n (%) 869 31,8 
Men, n (%) 1861 68,2 
Age, mean, years 46,15 7,5 
Non smoker, n (%) 693 58,6 
Smoker, n (%) 489 41,4 
Physical activity, n (%) 488 41,2 
Sedentary life, n (%) 695 58,8 
No alcohol, n (%) 699 59 
Alcohol use >20 g/day, n (%) 475 40,1 
Waist circumference, cm, mean  86,3 9,8 
Body mass index, kg/m2, mean  23,4 3,6 
No lipodistrophy, n (%) 563 26,4 
Lipoatrophy, n (%) 696 32,6 
Lipohypertrophy, n (%) 209 9,8 
Mixed Form, n (%) 668 31,3 
Fasting glucose, mg/dl, mean 96,2 20,2 
HOMA, median  2,4 1,4 - 4 
Triglycerides, mg/dl, median  138 96 - 203 
Total cholesterol, mg/dl, mean  191,8 44,8 
HDL cholesterol, mg/dl, mean  47,9 15,6 
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LDL cholesterol, mg/dl, mean  116,9 36,1 
CD4 nadir, c/µL, median  196 81 – 297,5 
Current CD4, c/µL, median 567 418 - 747,5 
CD4/CD8 ratio, median  0.71  0.48-1.00 
Cumulative exposure to NRTIs, 
months, median  
100 48 - 148 
Cumulative exposure to PIs, 
months, median (IQR) 
38 7 - 77 
Cumulative exposure to NNRTIs, 
months, median (IQR) 
18 0 - 56 
No hypertension, n (%) 1974 72,3 
Hypertension, n (%) 756 27,7 
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Figure legends 
 
Fig 1. Relationship between mean frailty index and current CD4 cell count. 
Using a Lowess smoothing curve, frailty index exhibited a hook-shaped relationship with 
current CD4 count. 
 
Fig 2. Relationship between mean frailty index and CD4/CD8 ratio. 
Frailty index exhibites a hook-shaped relationship with current CD4 count. 
 
Fig 3. GEE linear regression estimates in subpopulation with CD4/CD8 ratio. 
Panel A - GEE linear regression estimates for people with CD4 cell counts less than 
900/µL. Panel B - GEE linear regression estimates for those with CD4 cell counts >900/µL. 
 
 
